“IT IS ORDERED, ADJUDGED AND DECREED as follows: 1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties. 2. Hetero admits that the claims of the Patents-in-Suit are valid and enforceable with respect to products containing Apalutamide (the active pharmaceutical ingredient in the Hetero Product) as the sole active ingredient that are sold, offered for sale, or distributed under an Abbreviated New Drug Application that refers to the product sold pursuant to NDA No. 210951 as the reference-listed drug, and that the claims of the Patents-in-Suit would be infringed by the commercial manufacture, use, sale, offer for sale, or importation of the Hetero Product in the United States prior to the expiration of the Patents-in-Suit. Hetero and its affiliates are hereby enjoined from manufacturing, using, offering for sale, selling in the United States, or importing into the United States, the Hetero ANDA Product until the expiration of the Patents-in-Suit, including any patent term extensions and/or patent term adjustments and during the period of any associated pediatric exclusivity, other than as authorized by Plaintiffs. 4. All affirmative defenses, claims and counterclaims, which have been or could have been raised by Plaintiffs against Hetero and its affiliates, or by Hetero and its affiliates against Plaintiffs, in this litigation solely with respect to the Patents-in-Suit as asserted against the Hetero ANDA Product are hereby dismissed with prejudice. 5. Plaintiffs and Hetero shall bear their own fees and costs in connection with this litigation, including attorneys’ fees. 6. Plaintiffs and Hetero waive all right to appeal or otherwise move for relief from this Judgment and Order. 7. This Court shall retain jurisdiction of this litigation and over Plaintiffs and Hetero for purposes of enforcement of the provisions of this Judgment and Order.”